NCT07549542
Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement
Enrolling by Invitation
PHASE4Ages 18+InterventionalBasic scienceRutgers, The State University of New JerseyInvestigator-initiated
~25 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:CeFAZolin 1000 MGSaline (0.9%, sterile, for infusion)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cefazolin Concentration
Measured over From administration of intra-osseous ancef to 4 hours post-operatively
Conditions
Where it's being run
1 sites across 1 statesNew Jersey1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥ 18 years
Scheduled to undergo primary total hip arthroplasty
Receiving standard institutional antibiotic prophylaxis with IV bolus cefazolin prior to surgery
Exclusion
Reduced renal function (GFR \< 30)
Reduced liver function (AST/ALT \> 3× upper limit of normal)
Weight \> 120 kg
Undergoing bilateral total hip arthroplasty
Documented cefazolin anaphylaxis
Active joint infection
History of diabetes
Inflammatory arthropathies
Inability to understand written and/or spoken English
Undergoing revision total hip arthroplasty
What this trial measures
- Cefazolin ConcentrationFrom administration of intra-osseous ancef to 4 hours post-operatively
Cefazolin concentration in local tissues and serum